Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PelvEx II: Induction Chemotherapy for Locally Recurrent Rectal Cancer
NCT04389086Phase 3Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Nov 2020
- Primary completion
- Mar 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, capecitabine, folinic acid, fluorouracil and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: Proportion of patients with a clear resection margin. Started Nov 2020; status: recruiting.
02
Drugs
oxaliplatincapecitabinefolinic acidfluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04389086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389086.